SequelSEC

Grace Therapeutics, Inc. GRCE

Pharmaceutical Preparations · CIK 0001444192 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2022-03-31
Operating income
-$4.40M
Fiscal year ended 2022-03-31
Free cash flow
Unavailable
Fiscal year ended 2022-03-31

Grace Therapeutics, Inc. (GRCE) reported revenue of $0 and net income of -$3.90M for the fiscal year ended 2022-03-31. This page shows 4 annual periods of income statement, balance sheet and cash flow figures normalized from Grace Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Grace Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-03-312020-12-31
Revenue$0$0$115.00K$81.00K
Cost of revenue$0$0$40.00K$36.00K
Gross profit$0$0$75.00K$45.00K
Operating income-$4.40M-$4.47M-$2.30M-$1.96M
Net income-$3.90M-$3.78M-$5.65M-$3.22M
Research & development$2.33M$2.18M$453.00K$678.00K
Weighted-average diluted sharesshares 11.06Mshares 44.29MUnavailableUnavailable
Pretax income-$4.55M-$3.78MUnavailableUnavailable
Income tax expense-$648.00K$0UnavailableUnavailable
Diluted EPS$-0.04$-0.09UnavailableUnavailable
Selling, general & administrative$2.08M$2.05M$1.51M$1.33M
General & administrative$1.82M$1.81M$1.44M$1.10M
Selling & marketing$255.00K$238.00K$66.00K$226.00K

Balance

Grace Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-03-312020-12-31
Cash & equivalents$30.34M$33.01M$50.94M$26.55M
Total assets$128.62M$114.23M$62.46M$30.30M
Current assets$45.28M$49.00M$62.37M$30.20M
Total liabilities$20.35M$3.16M$6.80M$4.59M
Current liabilities$3.26M$2.90M$1.58M$2.25M
Total equity incl. NCI$108.27M$111.06M$55.66M$25.72M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailable$14.00K
Accounts receivable$548.00K$238.00K$530.00K$619.00K
Goodwill$12.96MUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable

Cash flow

Grace Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-03-312020-12-31
Operating cash flow-$3.14M-$4.58M-$1.76M-$4.21M
Capital expendituresUnavailableUnavailableUnavailableUnavailable
Investing cash flow$11.00K$557.00K-$8.42M-$1.37M
Financing cash flow$0$0$34.68M$19.74M
Net change in cash-$2.67M-$3.92M$24.40M$14.99M
Stock-based compensation$616.00K$454.00K$171.00K-$30.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailable

Derived

Grace Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2022-03-312021-12-312021-03-312020-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailable65.2%55.6%
Operating marginUnavailableUnavailable-2000.0%-2424.7%
FCF marginUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailable148.7%-37.0%
Current ratio13.89x16.91x39.50x13.43x
Revenue YoY growth-100.0%-100.0%UnavailableUnavailable
Net marginUnavailableUnavailable-4909.6%-3975.3%
R&D / revenueUnavailableUnavailable393.9%837.0%
CapEx / revenueUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GRCE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-K · Filed 2026-06-18View SEC filing
10-Q · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-K · Filed 2025-06-23View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

cash flow reconciliationreview2021-03-31

Operating, investing and financing flows differ from the reported change in cash by 8322000, beyond tolerance 1000000.

cash flow reconciliationreview2020-12-31

Operating, investing and financing flows differ from the reported change in cash by 1843000, beyond tolerance 1000000.